Company

Portfolio Data

Icon: back arrowBack to Company Search

AMUNIX, INC.

Address

500 Ellis Street, Suite B
MOUNTAIN VIEW, CA, 94043-
USA

UEI: N/A

Number of Employees: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

SBIR/STTR Involvement

Year of first award: 2007

3

Phase I Awards

2

Phase II Awards

66.67%

Conversion Rate

$366,097

Phase I Dollars

$2,006,044

Phase II Dollars

$2,372,141

Total Awarded

Awards

Up to 10 of the most recent awards are being displayed. To view all of this company's awards, visit the Award Data search page.

Seal of the Agency: HHS

XTENylation of enfuvirtide to generate a bio-better product with improved dosing

Amount: $157,550   Topic: NIAID

DESCRIPTION (provided by applicant): Enfuvirtide (Fuzeon, T-20) is a peptide HIV entry inhibitor currently dosed twice daily by subcutaneous injection. While proven to be efficacious and safe, enfuvirtide is under-utilized due to its frequent dosing, cumbersome administration, and inducement of injection site reactions in most patients. In expressing enfuvirtide as a recombinant XTEN fusion, we expect to improve all of these properties and create a longer-acting and more easily administered drug. Amunix hasdeveloped the XTEN technology platform to extend the serum half-lives of protein pharmaceuticals. XTEN is a synthetic, unstructured polypeptide chain that increases the apparent molecular weight of proteins to which it is fused, thereby slowing kidney clearance in a manner analogous to conjugation with polyethylene glycol (PEG). Obvious targets for XTEN are peptide drugs which, due to their small size, tend to be eliminated quickly via kidney filtration. XTEN prolongs exposure such that peptides normally dosed twice daily are projected to be administered monthly as XTEN fusions. Additionally, XTEN, due to its unstructured nature, is known to increase the solubility of and limi the aggregation of fused payloads. Modifying these drug properties simplifies manufacturing and use by enabling liquid, rather than lyophilized, formulation. Here, our goal is to combine XTEN with the validated anti-HIV drug enfuvirtide to produce a superior and more clinically relevant pharmaceutical. PUBLIC HEALTH RELEVANCE:Patients infected with HIV are healthiest when taking combination regimens containing drugs that work in different ways. Even though enfuvirtide, which works in a unique way, can be incorporated in these combination regimens, it has disadvantages that limit its inclusion. Here, we propose to use our XTEN technology to make a better version of enfuvirtide that is easier to use, causes fewer side effects, and is less expensive so that it can be taken by more patients.

Tagged as:

SBIR

Phase I

2012

HHS

NIH

Seal of the Agency: HHS

Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers

Amount: $1,010,920  

DESCRIPTION (provided by applicant): The market for protein-based biopharmaceuticals is rapidly expanding. However, the clinical utility of many proteins is limited by their short serum half-life, requiring frequent injections. The most common approach to improve serum half-life is PEGylation. The chemical conjugation of Polyethylene glycol (PEG) to therapeutic proteins typically results in product mixtures that include inactive isomers and reduce the overall potency of the product. The chemical PEGylation of proteins significantly increases manufacturing costs, requiring precise process control and analytical assays to ensure reproducibility of product composition. The current project describes polypeptide chains (called rPEGs) that mimic the physicochemica l properties of chemical PEG. rPEGs are hydrophilic and have very large hydrodynamic radii. Most importantly, rPEGs can be recombinantly fused to therapeutic proteins resulting in homogeneous products. The fusion of rPEGs to biopharmaceutical is expected t o provide benefits that are similar to chemical PEGylation (long serum half-life, reduced immunogenicity) while offering improved product potency, homogeneity, and significantly reduced manufacturing costs. Phase I of this project was extremely successful and demonstrated the feasibility of the rPEG technology. rPEG sequences that closely mimic the properties of chemical PEG were developed. We demonstrated that a 20 kDa rPEG sequence has an apparent molecular weight of 180 kDa. Fusion of rPEG to the model p rotein GFP increased its serum half-life in rats from 1-3 h to approximately 10 h, similar to the effect of chemical PEGylation. Furthermore, this rPEG-GFP fusion elicited only a very weak immune response in rats. Our phase II goal is to apply rPEG technol ogy to human growth hormone (hGH). hGH is currently used for the treatment of dwarfism in children. 2006 sales exceeded 3B. Due to its rapid plasma elimination, hGH treatment requires daily injections. No long-acting form of hGH has been approved and chem ical PEGylation of hGH had limited success due to the formation of mixtures containing inactive isomers. We aim to develop methods for the production, purification, and formulation of rPEG-hGH. The resulting product will be thoroughly characterized in vitr o and in vivo. The resulting data package will allow rPEG- hGH to enter clinical development. The methods and data developed during the project will validate rPEG technology and enable its broad application to other protein pharmaceuticals. PUBLIC H EALTH RELEVANCE: The utility of many biopharmaceuticals is limited by their short serum half-life, which requires frequent injections. The goal of this project is to develop recombinant peptide chains (called rPEG) that mimic the properties of polyethylene glycol. These rPEGs can be directly fused to protein pharmaceuticals to increase their serum half-life. We will validate rPEG technology by developing a long-acting version of human growth hormone for the treatment of dwarfism in children.

Tagged as:

SBIR

Phase II

2008

HHS

NIH

Seal of the Agency: HHS

Targeting toxins to tumors using microproteins

Amount: $995,124  

DESCRIPTION (provided by applicant): Treatment of metastatic tumors is a major health challenge. Recently, antibody-based therapies have been developed that are more specific and have fewer side effects compared with conventional chemotherapy. However, the potency of most antibody therapeutics is limited by their inadequate ability to kill tumor cells. Consequently, there is an urgent, unmet need to develop therapeutics that combine the specificity of antibodies for tumor tissues with a potent cytotoxic fun ction. The development of tumor-targeted toxins has yielded promising results and led to one approved product, Ontak (Denileukin). Most molecules however are immunogenic and aggregation prone, have limited stability and require complex manufacturing routes . To achieve clinical and commercial success it is critical for candidates to meet following criteria: 1) high potency; 2) low systemic toxicity; 3) low immunogenicity; 4) high protein stability, lack of aggregation; 5) robust manufacturing. This proposal aims to develop tumor-targeted toxins by combining three elements that confer significant advantages over current approaches: microproteins for tumor binding/internalization; RNAse for cell killing; rPEG to optimize PK properties. In the successful Phase I of this project, we developed tumor-specific microproteins with the following properties: 1) efficient production in E. coli; 2) efficient phage display that enables rapid specificity optimization; 3) effective internalization of toxic payloads; 4) excell ent serum stability. In a separate phase I SBIR project, we developed rPEGs, hydrophilic protein sequences that mimic the properties of chemical polyethylene glycol (PEG) but can be directly fused to other proteins. rPEGs optimize the pharmacokinetics of a product, reduce product immunogenicity, and greatly reduce protein aggregation. Our Phase II goal is to optimize the specificity of our lead microproteins to achieve a gt1000x ration of tumor/normal affinity. Subsequently, we will fuse these optimized mic roproteins to RNAse as toxic payload and rPEG to optimize PK, PD and protein manufacturing. The resulting fusion proteins will be thoroughly evaluated for in vitro and in vivo performance. In addition, we will develop an effective manufacturing process tha t can be transferred with minor modifications to a GMP manufacturer. We aim to generate two lead molecules that will be ready to enter preclinical followed by clinical development. In addition we will generate microprotein-rPEG fusions with defined conjuga tion sites that will be uniquely suitable for the chemical conjugation of toxic payloads. PUBLIC HEALTH RELEVANCE: The development of tumor-targeted toxins have yielded promising results and led to one approved product, Denileukin. However, existing molecules have significant limitations especially immunogenicity and complex manufacturing requirements. This project will use tumor-specific microproteins to address these limitations and develop targeted toxins with the following characteristics: 1) hig h potency; 2) low systemic toxicity; 3) low immunogenicity to allow repeat dosing; 4) good protein stability; 5) lack of aggregation; 6) robust manufacturing process.

Tagged as:

SBIR

Phase II

2008

HHS

NIH

Seal of the Agency: HHS

Drug binding microprotein domains for targeted delivery of cytotoxic drugs

Amount: $108,284  

DESCRIPTION (provided by applicant): Targeted delivery of cytotoxic drugs to tumor tissues is an effective strategy to minimize drug exposure of normal tissues and thus improve the toxicity and efficacy profiles of these agents. A tumor targeting system consists of a tumor recognition moiety linked to a cytotoxic payload. Antibody-drug conjugates represent the most advanced form of this approach. These systems are dependent on the chemical conjugation of drug molecules to the targeting moieties through various linker chemistries. The need for chemical modification and coupling steps adds significant cost and complexity to the manufacturing process. Additionally, there remain concerns that the linkers may have inappropriate stability profiles, the drugs may not be released in their active states or in quantities needed to achieve efficacy, and the conjugation process will perturb mAb binding characteristics. We thus seek a universal solution that would circumvent the need for complex chemical conjugation processes and that would be directly applicable to a wide variety of targeting modalities. We envision a protein-based domain that would bind small molecule drugs non-covalently. The binding and stability profile can be directly customized to the environment where the drug is targeted for release. Importantly, these drug-binding domains can be genetically fused to targeting domains. Microproteins, which are very small proteins with high disulfide bond densities, possess distinctive properties which make them particularly suited for this purpose. Their unique structure allows the accommodation of large degrees of both sequence and structural diversity. Their small sizes, stability and non-immunogenicity are also attractive therapeutic attributes. As an initial proof of concept, which can be immediately extended to a therapeutic product concept, we propose to develop microprotein domains that can specifically bind the commonly used cancer drug, doxorubicin, and release it in acidic or reducing environments - conditions which prevail after intracellular uptake and not within the systemic circulation. We have designed and constructed 10 phage display libraries based on different microprotein scaffold families. The total diversity in these libraries exceeds 1011 unique sequences. We plan to test the feasibility of our approach through the systematic set of specific aims below. 1) Pan phage display libraries for microprotein-displaying phages which bind to immobilized doxorubicin. 2) Confirm ability of enriched microproteins to specifically bind to immobilized doxorubicin. Our goal is to identify at least 5 different lead variants. 3) Characterize binding properties and serum stability of the selected microproteins. Completion of these Phase I milestones will enable us to obtain important proof of concept and validation of our strategy for developing microproteins as drug-binding domains for targeted delivery of cancer therapeutics. Our ultimate goal would be to advance optimized microprotein drug-binding domains, which are fused to clinically important targeting moieties with specificity for tumor antigens such as CD22, CD30, or CD74, into clinical studies.

Tagged as:

SBIR

Phase I

2007

HHS

NIH

Seal of the Agency: HHS

Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers

Amount: $100,263  

DESCRIPTION (provided by applicant): Protein drugs have been approved for many therapeutic indications and represent a rapidly growing segment of the pharmaceutical industry. However, many approved protein drugs and candidates in development fail to reach their potential efficacy due to suboptimal pharmacokinetic properties and immunogenicity concerns. These properties include short circulating half-lives, short shelf lives, low solubility, rapid kidney clearance and susceptibility to proteolytic degradation. The modification of proteins with hydrophilic chemical polymers like polyethylene glycol (PEG) is a clinically validated approach to addressing these limitations. However, the challenges associated with chemical modification procedures required for the attachment of these polymers present significant challenges. Our ultimate goal is to generate amino acid sequences that mimic the physiochemical properties of hydrophilic chemical polymers like PEG. Our proposal is based on the observation that glycine rich sequences (GRS) which contain few hydrophobic amino acids will not fold into compact 3-dimensional structures but will adopt random conformations with large hydrodynamic radii similar to PEG. We hypothesize that they will confer similar pharmacokinetic improvements when attached to therapeutic proteins. These sequences can be attached to proteins using conventional recombinant technology and thus completely obviates the need for chemical modifications steps. We have synthesized a 198 amino acid glycine rich sequence based on sequences that occur in human proteins. We aim to express this protein and systematically test its physiochemical and biological properties relevant to pharmacokinetic enhancement. Our specific aims are: 1) Produce 5 mg of a purified GRS protein in E. coli expression system for downstream characterization and studies. 2) Characterize serum stability, protease resistance and biophysical properties of the GRS protein. 3) Characterize plasma pharmacokinetics and immunogenic potential of the GRS protein in animal models. In Phase II, we will perform detailed optimization of GRS for high-level expression, plasma half-life extension and reduced immunogenicity. We aim to advance optimized GRS which are fused to pharmaceutically active proteins like interferon-alpha or G-CSF into animal and clinical studies. Our ultimate goal is to validate and make this method readily applicable to therapeutic proteins. Our project aims to generate glycine rich sequences that can be attached recombinantly to therapeutic proteins to improve their pharmacokinetic properties. This approach would circumvent the difficulties associated with the modifying proteins with hydrophilic polymers like PEG.

Tagged as:

SBIR

Phase I

2007

HHS

NIH